Skip to main content
HLB bioStep Co.,Ltd. logo

HLB bioStep Co.,Ltd. — Investor Relations & Filings

Ticker · 278650 ISIN · KR7278650007 KO Professional, scientific and technical activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2025-03-18 Audit Report / Informat…
Country KR South Korea
Listing KO 278650

About HLB bioStep Co.,Ltd.

http://hlbbiostep.com/en/

HLB bioStep Co.,Ltd. is a non-clinical Contract Research Organization (CRO) that provides a range of testing services to pharmaceutical companies and bio ventures. The company's core services support new drug development and include efficacy testing, pharmacokinetic/toxicokinetic (PK/TK) studies, and toxicology evaluations. A key area of specialization is veterinary medicine; HLB bioStep is an institution approved to conduct non-clinical tests and clinical trials for veterinary drugs. It also offers consulting services for regulatory approval procedures. The company utilizes various platform technologies, such as cell-enzyme-based screening and xenograft assays, and provides a comprehensive 'One-Stop Service' that leverages its experience in building laboratory facilities.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from HLB BioStep. It provides a summary of financial statements, audit opinions, and key financial metrics (assets, liabilities, profit/loss) for the current and previous fiscal years. While it contains financial data, it is a standard regulatory disclosure announcement in the Korean market (DART system) notifying the public that the audit report has been submitted. According to the 'Menu vs Meal' rule, this is an announcement of the report rather than the full audit report document itself, fitting the criteria for a Regulatory Filing (RNS). FY 2024
2025-03-18 Korean
사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) for HLB bioStep Co., Ltd. for the fiscal year 2024 (Jan 1, 2024 to Dec 31, 2024). It follows the standard structure of a comprehensive annual report, including company overview, history, capital changes, and governance details, which corresponds to the 10-K filing category in the provided schema. FY 2024
2025-03-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory disclosure for insider trading or changes in share ownership by company directors/executives. According to the provided definitions, this falls under 'Director's Dealing' (DIRS).
2025-03-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (FSS) in Korea. It details the share acquisition (장내매수) by an executive (Kim Jong-Ho) of HLB Biostep. This type of filing is specifically categorized as a Director's Dealing (DIRS) report, as it documents insider transactions by company management.
2025-03-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is specifically used to report insider transactions, such as the exercise of stock options by a director (in this case, Myungjin Kim of HLB Biostep). This falls under the 'Director's Dealing' category.
2025-03-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. It details a change in share ownership by an executive (Jin Yang-gon) of HLB BioStep. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) as it reports personal share transactions by company directors/executives.
2025-03-12 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.